Oral ﬂuoxetine in the management of amblyopic patients aged between 10 and 40 years old
Background and Aim: The objective of this study is to assess the efﬁcacy of oral ﬂuoxetine therapy in improving the visual function of amblyopic patients aged between 10 and 40 years old.
Methods: In this double-blinded, randomized, controlled trial (IRCT2016052428046N1; registered retrospectively), 40 eligible participants with anisometropic or mixed amblyopia were randomly assigned to either ﬂuoxetine or placebo groups. Participants with anisometropia and logMAR best spectacle-corrected visual acuity (BSCVA) worse than 0.2 logMAR in the amblyopic eye or at least a two-line of difference in the BSCVA between the fellow eyes were included. Participants with signiﬁcant ocular or systemic diseases were excluded. In both groups, the better eye of each patient was patched for 4 – 6 h a day during the study period. Participants in the treatment group were treated with oral ﬂuoxetine for 3 months. Change in the Snellen BSCVA (after 3 months) was regarded as the primary outcome measure.
Results: Data from 20 participants in the ﬂuoxetine group and 15 participants from the placebo group were analyzed (aged 11 – 37 years). The magnitude of improvement in visual acuity (from baseline to 3 months after treatment) was signiﬁcantly higher in the ﬂuoxetine group (0.240 ± 0.068 logMAR; 2.4 line-gain) compared with the control group (0.120 ± 0.086 logMAR; 1.2 line-gain).
Conclusion: This study suggests beneﬁcial effects of ﬂuoxetine in the management of adult and adolescent amblyopia.
Mohammad Hossein Sharif1 , Mohammad Reza Talebnejad2 *, Karim Rastegar3 , Mohammad Reza Khalili2 , M. Hossein Nowroozzadeh2